Figure 1



Heart rate
beats per minute
415
385
355
325
0
4
8
12
Time (weeks)
†
†
HF (untreated)
HF + A
HF + perindopril
HF + A + perindopril
† p<0.05 vs HF

Figure 2



Shortening fraction of the left ventricle
% of the diameter of the ventricle
30
20
10
0
0
4
8
12
Time (weeks)
†
Heart rate
(mL/min)
150
120
90
60
0
4
8
12
Time (weeks)
†
†
HF (untreated)
HF + A
HF + perindopril
HF + A + perindopril
† p<0.05 vs HF

Figure 3



LVESP
millimetres of mercury
160
120
80
40
0
dP/dt$_{max}$
10^3mm of mercry/second
12
8
4
0
LVESPVR
mmHg/RVU
30
20
10
0
control
HF (untreated)
HF + A
HF + perindopril
HF + A + perindopril
* p<0.05 vs control
† p<0.05 vs HF
‡ p<0.05 vs HF + A
p<0.05 vs HF + perindopril
LVEDP
millimetres of mercury
12
8
4
0
dP/dt$_{min}$
-10^3mm of mercury/second
Tau
milliseconds
15
10
5
0
LVEDPVR
mmHg/RVU
9
6
3
0

Figure 4a




LVESP
dP/dt$_{max}$
LVESPVR
millimetres of mercury
180
120
60
0
10^3 mm of mercury/second
12
8
4
0
mmHg/RVU
30
20
10
0
control
HF (untreated)
HF + perindopril
HF + ivabradine + perindopril
* p<0.05 vs control
† p<0.05 vs HF
‡ p<0.05 vs HF + perindopril
LVEDP
dP/dt$_{min}$
Tau
LVEDPVR
millimetres of mercury
20
15
10
5
0
-10^3 mm of mercury/second
12
8
4
0
milliseconds
15
10
5
0
mmHg/RVU
6
4
2
0

Figure 4b


LVESPVR
LVEDPVR
mmHg/RVU
40
30
20
10
0
6
4
2
0
control
HF (untreated)
HF + ivabradine
* p<0.05 vs control
† p<0.05 vs HF